A trade name , trading name , or business name is a pseudonym used by companies that do not operate under their registered company name. The term for this type of alternative name is fictitious business name . Registering the fictitious name with a relevant government body is often required.
77-1483: The Bristol-Myers Squibb Company , doing business as Bristol Myers Squibb ( BMS ), is an American multinational pharmaceutical company . Headquartered in Princeton, New Jersey , BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $ 46.2 billion. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer , HIV/AIDS , cardiovascular disease , diabetes , hepatitis , rheumatoid arthritis , and psychiatric disorders . BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton ), Summit, New Jersey , formerly HQ of Celgene , New Brunswick, New Jersey , Redwood City, California , and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts , Braine-l'Alleud , Belgium, Tokyo , Japan, Hyderabad ; Bangalore , India and Wirral , United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers). The Squibb corporation
154-546: A 122.5% premium to its last closing price), helping to boost its complement of cancer drugs, specifically repotrectinib . That same month, the company announced it would be investing $ 180m in French AI company Owkin , to design potentially more precise and efficient clinical trials. The collaboration will initially focus on cardiovascular diseases, and has the potential to extend into projects in other therapeutic areas. In August 2023, Bristol Myers Squibb partnered with Cellares for
231-420: A DBA must be registered with a local or state government, or both, depending on the jurisdiction. For example, California, Texas and Virginia require a DBA to be registered with each county (or independent city in the case of Virginia) where the owner does business. Maryland and Colorado have DBAs registered with a state agency. Virginia also requires corporations and LLCs to file a copy of their registration with
308-467: A DBA statement, though names including the first and last name of the owner may be accepted. This also reduces the possibility of two local businesses operating under the same name, although some jurisdictions do not provide exclusivity for a name, or may allow more than one party to register the same name. Note, though, that this is not a substitute for filing a trademark application. A DBA filing carries no legal weight in establishing trademark rights. In
385-516: A businessperson writes a trade name on a contract, invoice, or cheque, they must also add the legal name of the business. Numbered companies will very often operate as something other than their legal name, which is unrecognizable to the public. In Chile , a trade name is known as a nombre de fantasía ('fantasy' or 'fiction' name), and the legal name of business is called a razón social (social name). In Ireland , businesses are legally required to register business names where these differ from
462-573: A deferred prosecution agreement, the company was placed under the oversight of a monitor appointed by the U.S. attorney in New Jersey. In addition, the former head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations. In July 2006, an investigation of the company was made public, and the FBI raided the company's corporate offices. The investigation centered on
539-465: A flagellum or pilli, and therefore is an immobile microbe. L. acidophilus is a homofermentative anaerobic microorganism, meaning it only produces lactic acid as an end product of fermentation; and that it can only ferment hexoses (not pentoses) by way of the EMP pathway (glycolysis). L. acidophilus has a slower growth time in milk than when in a host due to limited available nutrients. Because of its use as
616-413: A large cell wall consisting of peptidoglycan exterior to the membrane. The cell wall of L. acidophilus is interwoven with teichoic acids and surface proteins, with anionic and neutral polysaccharides as well as an S-layer lining the exterior of the cell. The S-layer proteins of L. acidophilus have been shown to adhere to epithelial cells as well as mucus and other extracellular proteins. The S-layer
693-701: A major supplier of medical goods to the Union Army during the American Civil War , providing portable medical kits containing morphine , surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the Eastern United States at that time). In 1944, Squibb opened the world's largest penicillin plant in New Brunswick, New Jersey . In 1887, Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased
770-423: A multiyear program of on-going layoffs. This was part of a business strategy launched in 2007 to transform the company from a large, diversified pharmaceutical company to a specialty biopharma company, which also included the closure of half of their manufacturing facilities. As another cost-cutting measure, Bristol-Myers Squibb also reduced health-care subsidies for retirees and planned to freeze their pension plan at
847-410: A positive impact on the species makeup of a gut microbial community, providing the organism with intestinal health benefits. The innate immune system of L. acidophilus also produces antimicrobial peptides. The group of short peptides found there have shown antimicrobial properties such as their strength against viruses and other cell types, including cancer cells. There is also some evidence supporting
SECTION 10
#1733092563337924-459: A probiotic in milk, a study done by the American Journal of Dairy Science examined the nutrient requirements of L. acidophilus in an effort to increase its low growth rate. The study found that glucose and the amino acids cysteine , glutamic acid , isoleucine , leucine , lysine , methionine , phenylalanine , threonine , tyrosine , valine , and arginine are essential nutrients to
1001-612: A producer of acidophilus milk in East Syracuse, New York , and converted the plant to produce penicillin for the World War II Allied forces . After the war, the company renamed the plant Bristol Laboratories in 1945 and entered the civilian antibiotics market, where it faced competition from Squibb. Penicillin production at the East Syracuse plant ended in 2005, when it became less expensive to produce overseas. As of 2010,
1078-646: A refresher to the company's pipeline, helping to overcome from declining sales of Opdivo relative to competitor Keytruda . Under the terms of the deal, Celgene shareholders would receive one BMS share as well as $ 50 in cash for each Celgene share held, valuing Celgene at $ 102.43 a share; representing a 54% premium to the previous days closing price. Investor opposition to this acquisition, leading into an 12 April shareholder vote, appeared when BMS's second-largest investor, Wellington Management , voiced its opposition, followed by investor Starboard Value . In April 2019 BMS announced that 75% of its shareholders voted to approve
1155-458: A registered legal name and a fictitious business name, or trade name, is important because fictitious business names do not always identify the entity that is legally responsible . Legal agreements (such as contracts ) are normally made using the registered legal name of the business. If a corporation fails to consistently adhere to such important legal formalities like using its registered legal name in contracts, it may be subject to piercing of
1232-542: A stake in the company, signaling a potential future takeover from the likes of Gilead Sciences . In April 2018, the company reported net income of $ 1.5 billion, or 91 cents per share, for the first quarter of the year, thanks to the increased sales of their cancer drug Opdivo. In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships, and acquisitions. In November 2009, Bristol Myers Squibb announced that it
1309-539: Is a commercial strain and probiotic that is widely used in the dairy industry to obtain high-quality fermentation products." Increased levels of beneficial bacteria, and decreased levels of pathogenic bacteria within the intestine due to the consumption of fermented milk containing strains of L. acidophilus has a range of probiotic effects. Reduced serum cholesterol levels, stimulated immune response, and improved lactic acid digestion are all probiotic effects associated with intestinal L. acidophilus presence . L. acidophilus
1386-454: Is also sometimes used. A company typically uses a trade name to conduct business using a simpler name rather than using their formal and often lengthier name. Trade names are also used when a preferred name cannot be registered, often because it may already be registered or is too similar to a name that is already registered. Using one or more fictitious business names does not create additional separate legal entities. The distinction between
1463-400: Is also very well suited for living in a dairy medium, as fermented milk is the ideal method of delivery for introducing L. acidophilus into a gut microbiome. The viability of L. acidophilus cells encapsulated by spray drying technology stored at refrigerated condition (4 °C) is higher than the viability of cells stored at room temperature (25 °C). Quorum sensing among cells is
1540-435: Is called a razón social . Acidophilus Lactobacillus acidophilus ( Neo-Latin 'acid-loving milk-bacillus') is a rod-shaped, Gram-positive , homofermentative , anaerobic microbe first isolated from infant feces in the year 1900. The species is commonly found in humans, specifically the gastrointestinal tract and oral cavity as well as some speciality fermented foods such as fermented milk or yogurt, though it
1617-461: Is distinguishable when recognizing how the prokaryote replicates its DNA during replication . In L. acidophilus, replication begins at an origin called oriC and moves bi-directionally in the form of replication forks . The DNA is synthesized continuously on the leading strand and in discontinuous Okazaki fragments on the lagging strand with help from the DNA polymerase III enzyme. An RNA primer
SECTION 20
#17330925633371694-551: Is extremely important to cell yield during the fermentation process, and genetic testing on L. acidophilus in order to increase its temperature tolerance is currently being done. When being considered as a probiotic, it is important for L. acidophilus to have traits suitable for life in the gastrointestinal tract. Tolerance of low pH and high toxicity levels are often required. These traits vary and are strain specific. Mechanisms by which these tolerances are expressed include differences in cell wall structure, along with other changes
1771-630: Is made of two structural domains. The C-terminal domain is responsible for cell wall anchoring, while the N-terminal domain is responsible for interacting with the cell environment, as well as S-layer self assembly. In the L. acidophilus species, the N-terminal region shows high amino acid variability along with low sequence homology (31-72%). However, the C-terminus shows low amino acid variability and high amino acid sequence homology (77-99%). L. acidophilus does not have any extracellular means of motion like
1848-566: Is needed to initiate the DNA synthesis on the leading and lagging strands. DNA polymerase III follows the RNA primer with the synthesis of DNA in the 5' to 3' direction. L. acidophilus consists of a small genome with a low guanine-cytosine content, approximately 30%. A study comparing 46 genomes of varying strains of L. acidophilus found the genome size ranged from 1.95 Mb to 2.09 Mb, with an average size of 1.98 Mb. The average number of coding sequences in
1925-497: Is not the most common species for this. The species most readily grows at low pH levels (below 5.0), and has an optimum growth temperature of 37 °C. Certain strains of L. acidophilus show strong probiotic effects, and are commercially used in dairy production. The genome of L. acidophilus has been sequenced. L. acidophilus has antagonistic effects on the growth of Staphylococcus aureus , Escherichia coli , Salmonella typhimurium , and Clostridium perfringens . Out of
2002-556: Is protein expression. Changes in salt concentration have been shown to affect L. acidophilus viability, but only after exposure to higher salt concentrations. In another experiment highlighted by the American Dairy Science Association, viable cell counts only showed a significant reduction after exposure to NaCl concentrations of 7.5% or higher. Cells were also observed to distinctly elongate when grown in conditions of 10% NaCl concentration or higher. L. acidophilus
2079-490: Is the first novel type of treatment for the devitalizing, chronic mental disorder in the last 70 years. The following is an illustration of the company's major mergers and acquisitions and historical predecessors: For the fiscal year 2018,Bristol Myers Squibb reported earnings of US$ 1.007 billion, with an annual revenue of US$ 20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $ 55 per share, and its market capitalization
2156-568: Is unclear because this species of Lactobacilli has also been found not to have a very strong ability to adhere to (and thereby colonize) the vaginal cells. Research has shown that the presence of L. acidophilus can produce a variety of probiotic effects in humans, such as acting as a barrier against pathogens, assisting in lactose digestion, enhancing immune response, and reducing cholesterol level. L. acidophilus must exist in concentrations of 10^5 - 10^6 c.f.u (colony-forming units) per mL in order for these effects to be seen. A study conducted at
2233-592: The FDA accepted Karuna Therapeutics' NDA for KarXT, for the treatment of schizophrenia in adults. The acquisition of Karuna Therapeutics was completed in March 2024. The company entered into an agreement to purchase RayzeBio, for approximately $ 4.1 billion, in December 2023. On 26 September 2024, The Food and Drug Administration has given approval to one of Bristol Myers Squibb’s most anticipated schizophrenia drugs named Cobenfy which
2310-459: The United Kingdom , there is no filing requirement for a "business name", defined as "any name under which someone carries on business" that, for a company or limited liability partnership, "is not its registered name", but there are requirements for disclosure of the owner's true name and some restrictions on the use of certain names. A minority of U.S. states, including Washington , still use
2387-648: The Wake Forest School of Medicine examined the effects of L. acidophilus on the structure and composition of the gut microbiome of mice with respect to the age of the mice. The research established the importance of the interactions between microbes within a gut microbial environment on the overall health of the organism, and the data showed that mice supplemented with L. acidophilus had reduced proteobacteria levels, and increased levels of other probiotic bacteria when compared to other mice of similar age. Another study conducted at Maranatha Christian University studied
Bristol Myers Squibb - Misplaced Pages Continue
2464-578: The cardiovascular disease drug developer Cardioxyl for up to $ 2.075 billion. The deal strengthens the BMS' critical pipelines with the phase II candidate for acute decompensated heart failure , CXL-1427 . In March 2016, the company announced it would acquire Padlock Therapeutics for up to $ 600 million. In early July, the company announced it would acquire Cormorant Pharmaceuticals for $ 520 million, boosting BMS' oncology offering through Cormorants monoclonal antibody targeted against interleukin-8 . In August 2017
2541-406: The luxS -mediated quorum sensing is involved in the regulation of behavior. In monoculture, the production of luxS increased during the exponential growth phase and started to plateau as it progressed to the stationary phase. Up-regulation of luxS can occur when L. acidophilus is placed in co-cultivation with another Lactobacillus species. Lactobacillus acidophilus is relatively rare in
2618-413: The vaginal microbiome ; it is more common in the gut. Other species in the genus are more common, including Lactobacillus crispatus , Lactobacillus gasseri , Lactobacillus jensenii , and Lactobacillus iners . In experiments, L. acidophilus seemed to decrease Candida albicans ’ ability to adhere to vaginal epithelial cells; however, L. acidophilus ’ use in preventing yeast infections
2695-775: The Clinton Pharmaceutical company of Clinton , New York. In May 1898, they decided to rename it Bristol, Myers and Company . Following Myers' death in 1899, Bristol changed the name to the Bristol-Myers Corporation . During the 1890s, the company introduced its first nationally recognized product Sal Hepatica , a laxative mineral salt, followed by Ipana toothpaste in 1901. Other divisions were Clairol (hair colors and haircare) and Drackett (household products such as Windex and Drano ). In 1943, Bristol-Myers acquired Cheplin Biological Laboratories,
2772-418: The U.S., trademark rights are acquired by use in commerce, but there can be substantial benefits to filing a trademark application. Sole proprietors are the most common users of DBAs. Sole proprietors are individual business owners who run their businesses themselves. Since most people in these circumstances use a business name other than their own name, it is often necessary for them to get DBAs. Generally,
2849-516: The business announced it would acquire Forbius and its TGF-beta 1 & TGF-beta 3 inhibitors. In October, BMS announced it would acquire cardiology company MyoKardia for $ 13.1 billion ($ 225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: danicamtiv (MYK-491) and MYK-224 . In June 2022, BMS announced it would acquire Turning Point Therapeutics Inc for $ 4.1 billion in cash ($ 76 per share,
2926-689: The case of L. acidophilus. Genetic analysis also revealed that all L. acidophilus strains contained at least 15 families of glycosyl hydrolases, which are the key enzymes in carbohydrate metabolism. Each of the 15 GH families were involved in metabolizing common carbohydrates, such as glucose, galactose, fructose, sucrose, starch, and maltose. Genes encoding antibiotic resistance by means of antibiotic efflux, antibiotic target alteration, and antibiotic target protection were present in all L. acidophilus strains, providing protection against 18 different classes of antibiotic across all strains. Fluoroquinolone, glycopeptide, lincosamide, macrolide and tetracycline were
3003-481: The company acquired IFM Therapeutics for $ 300 million upfront, with contingency payments of $ 1.01 billion due on certain milestones – allowing BMS to better compete against Merck & Co 's cancer rival treatment, Keytruda . In early January 2019, the company announced it would acquire Celgene (NASDAQ:CELG) for $ 74 billion ($ 95 billion including debt), in a deal that would become the largest pharmaceutical-company acquisition ever. The Celgene acquisition aimed to be
3080-482: The company for matters covered by the DPA. Under CEO Jim Cornelius, who was CEO following Dolan until May 2010, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company. In 2009, the company began a major restructuring focusing on the pharmaceutical business and biologic products, along with productivity initiatives and cost-cutting and streamlining business operations through
3157-569: The company obtained an exclusive opportunity to both licence and commercialise PROSTVAC , Bavarian Nordic 's phase III prostate-specific antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $ 60 million and incremental payments up to $ 230 million, if the overall survival of test patients exceeds that seen in Phase II tests. Bavarian could also receive milestone payments of between $ 110 million and $ 495 million, dependent on regulatory authorization, and these payments have
Bristol Myers Squibb - Misplaced Pages Continue
3234-484: The corporate veil . In English , trade names are generally treated as proper nouns . In Argentina , a trade name is known as a nombre de fantasía ('fantasy' or 'fiction' name), and the legal name of business is called a razón social (social name). In Brazil , a trade name is known as a nome fantasia ('fantasy' or 'fiction' name), and the legal name of business is called razão social (social name). In some Canadian jurisdictions , such as Ontario , when
3311-522: The county or city to be registered with the State Corporation Commission. DBA statements are often used in conjunction with a franchise . The franchisee will have a legal name under which it may sue and be sued, but will conduct business under the franchiser's brand name (which the public would recognize). A typical real-world example can be found in a well-known pricing mistake case, Donovan v. RRL Corp. , 26 Cal. 4th 261 (2001), where
3388-558: The distribution of Plavix and charges of collusion . On 12 September 2006, the monitor, former Federal Judge Frederick B. Lacey , urged the company to remove then-CEO Peter Dolan over the Plavix dispute. Later that day, BMS announced that Dolan would indeed step down. The deferred prosecution agreement expired in June 2007 and the Department of Justice did not take any further legal action against
3465-532: The end of 2009. BMS is a Fortune 500 Company (#114 in 2010 list). Newsweek's 2009 Green Ranking recognized Bristol-Myers Squibb as eighth among 500 of the largest United States corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies. Lamberto Andreotti was named CEO in 2010; he had previously served as "president and COO responsible for all pharmaceutical operations worldwide." In 2010, Lou Schmukler joined Bristol-Myers Squibb as
3542-572: The facility was used for the manufacturing process development and production of other biologic medicines for clinical trials and commercial use. In 1989, Bristol-Myers and Squibb merged and became Bristol-Myers Squibb. In 1999, then-U.S. President Bill Clinton awarded Bristol-Myers Squibb the National Medal of Technology , the nation's highest recognition for technological achievement, "for extending, and enhancing human life through innovative pharmaceutical research and development and for redefining
3619-630: The five classes of antibiotic to which L. acidophilus displayed the highest level of tolerance, with more than 300 genes relevant to these classes. L. acidophilus grows naturally in the oral, intestinal, and vaginal cavities of mammals. Nearly all Lactobacillus species have special mechanisms for heat resistance which involves enhancing the activity of chaperones . Chaperones are highly conserved stress proteins that allow for enhanced resistance to elevated temperatures, ribosome stability, temperature sensing, and control of ribosomal function at high temperatures. This ability to function at high temperatures
3696-439: The four organisms, Staphylococcus aureus is the most affected. Along with S. aureus , the other Gram-positive bacteria, C. perfringens, was affected more by L. acidophilus, than the two other bacteria that are Gram-negative. L. acidophilus is found to also reduce oral plaque formation by Streptococcus mutans . Lactobacillus acidophilus was first isolated from the human gastrointestinal tract in 1900 by Ernst Moro with
3773-568: The fundamentals of pharmacy are found in many medical papers of the late 1800s. The American Journal of Pharmacy published more than one hundred papers of Squibb's research surrounding the industry. The sons of Edward Squibb sold the company to Lowell M. Palmer and Theodore Weicker in 1905, who incorporated the company. Around this time, the Squibb logo was developed, which represented the company's products of "uniformity, purity, efficacy, and reliability based on research." Squibb Corporation served as
3850-440: The genome was 1780, with the strains isolated from fermented foods and commercial probiotics having more coding sequences on average than those isolated from humans. L. acidophilus has an open state pan-genome (all of the genes within a species), meaning that the pan-genome size increased as the number of genomes sequenced increased. The core-genome (the genes shared by all individuals of a species) consist of around 1117 genes in
3927-426: The growth of L. acidophilus , with glycine , calcium-pantothenate, and Mn acting as stimulatory nutrients. The study helps to explain the low growth rate of L. acidophilus in milk, as some of the amino acids necessary to L. acidophilus growth are lacking in milk. Adding amino acids with high rates of consumption to fermented milk is a possible solution to the problem. The specialization of prokaryotic genomes
SECTION 50
#17330925633374004-406: The impact of L. acidophilus cell free supernatants (a liquid medium containing the metabolites produced by microbial growth) on the growth pattern of Salmonella typhi , the microbe associated with Typhoid fever. The study showed that the presence of L. acidophilus metabolites significantly inhibited the growth curves displayed by S. typhi , supporting the idea that L. acidophilus presence has
4081-465: The large amount of information discovered about L. acidophilus NCFM, the US Food and Drug Administration has adjudged the microbe to be an approved ingredient in beverages, dairy products, and other probiotic foods. Lactobacillus acidophilus is an immobile rod-shaped (bacillus), gram-positive organism that ranges in size from 2-10 μm in size. L. acidophilus has one phospholipid bilayer membrane with
4158-402: The law is to protect the public from fraud, by compelling the business owner to first file or register his fictitious business name with the county clerk, and then making a further public record of it by publishing it in a newspaper. Several other states, such as Illinois , require print notices as well. In Uruguay , a trade name is known as a nombre fantasía , and the legal name of business
4235-461: The named defendant, RRL Corporation, was a Lexus car dealership doing business as " Lexus of Westminster ", but remaining a separate legal entity from Lexus, a division of Toyota Motor Sales, USA, Inc. . In California , filing a DBA statement also requires that a notice of the fictitious name be published in local newspapers for some set period of time to inform the public of the owner's intent to operate under an assumed name . The intention of
4312-436: The original name Bacillus acidophilus. Over time, there have been many changes to the methods for characterizing taxonomy of organisms, leading to the genus distinction of Lactobacillus in 1929. Complication around finding the original strain arose when multiple strains of a single isolate were given a variety of names. Most studies on L. acidophilus was focused on one particular strain, Lactobacillus acidophilus NCFM. With
4389-515: The pending merger with Celgene. Transaction to close in the third quarter of 2019, subject to regulatory approvals. Newly issued BMS shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol 'BMYRT'. The strategic divestment of the company's consumer health business, UPSA, to Taisho completed in 2019. UPSA focused product delivery on France and
4466-426: The potential to total up to $ 975 million. In May 2015, Dr. Giovanni Caforio became CEO of the company; Caforio was formerly the company's COO and succeeded Andreotti upon his retirement. Andreotti subsequently succeeded James Cornelius as executive chairman upon his retirement. In late February 2017, The Wall Street Journal and Fortune , among others, reported that activist investor Carl Icahn had taken
4543-420: The president of global product development and design. Schmukler led the team that completed the company's strategic transformation to a specialty biopharmaceutical company that had begun in 2007. As of 2011, the company had a dozen manufacturing facilities and six product development sites. Citing major developments and a market capitalization of US$ 87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb
4620-495: The previous 20 trading days ended on 6 January. On 29 June, BMS extended its portfolio of diabetes treatments when it agreed to buy Amylin Pharmaceuticals for around US$ 5.3 billion in cash and pay US$ 1.7 billion to Eli Lilly to cover Amylin's debt and its outstanding collaboration-related obligations. AstraZeneca , which already collaborated on several diabetes treatments with BMS, agreed to pay US$ 3.4 billion in cash for
4697-542: The process among which cell signaling can lead to coordinated activities which can ultimately help bacteria control gene expression in a consecutive sequence. This is accomplished via detection of small autoinducers which are secreted in response to increasing cell-population density. In Lactobacillus acidophilus, which can be found in the gastrointestinal tract, quorum sensing is important for bacterial interaction when considering biofilm formation and toxin secretion. In L. acidophilus , along with many other bacteria,
SECTION 60
#17330925633374774-576: The rest of Europe. As early as 2005, the company had divested individual consumer products, and its US- and Canada-focused consumer products business. In August, the Amgen announced it would acquire the Otezla drug programme from Celgene for $ 13.4 billion, as part of Celgene and BMS's merger deal. In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines. In August,
4851-418: The right to continue development of Amylin's products. Two years later, the company divested Amylin to AstraZeneca. In April 2014, BMS announced its acquisition of iPierian for up to $ 725 million. In February 2015, the company acquired Flexus Biosciences for $ 1.25 billion. As part of this deal, BMS will gain full rights to Flexus' lead small molecule IDO1-inhibitor , F001287. In November, the company acquired
4928-424: The robotic production of CAR-T treatments of which it has two approved. In September 2023, BMS announced it would pay Zenas BioPharma $ 50m upfront for a strategic license and collaboration to develop and commercialise obexelimab , a novel, bi-functional antibody for autoimmune diseases. In October 2023, BMS agreed to acquire Mirati Therapeutics , an American biotechnology company that develops targeted therapies for
5005-406: The science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." In 2002, the company was involved in a lawsuit of illegally maintaining a monopoly on Taxol , its cancer treatment, and it was again sued for the antitrust lawsuit five years later, which cost the company $ 125 million for settlement. Also in 2002, Bristol-Myers Squibb
5082-454: The surname(s) of the sole trader or partners, or the legal name of a company. The Companies Registration Office publishes a searchable register of such business names. In Japan , the word yagō ( 屋号 ) is used. In Colonial Nigeria , certain tribes had members that used a variety of trading names to conduct business with the Europeans. Two examples were King Perekule VII of Bonny , who
5159-469: The term trade name to refer to "doing business as" (DBA) names. In most U.S. states now, however, DBAs are officially referred to using other terms. Almost half of the states, including New York and Oregon , use the terms assumed business name or assumed name ; nearly as many, including Pennsylvania , use the term fictitious name . For consumer protection purposes, many U.S. jurisdictions require businesses operating with fictitious names to file
5236-513: The treatment of cancer, in an all-cash deal worth $ 4.8 billion, and an additional $ 1 billion in milestone payment. The acquisition was completed in January 2024. In December 2023, BMS signed an agreement for the acquisition of Karuna Therapeutics for an equity value totaling $ 14 billion. The acquisition included Karuna's lead asset, KarXT , an investigational muscarinic antipsychotic combination of Xanomeline and Trospium . In November 2023,
5313-625: The twelve months ending 31 December 2020 at 278 Kt (-6 /-2.1% y-o-y). The company aims to become net neutral carbon by 2040. Trade name In a number of countries, the phrase " trading as " (abbreviated to t/a ) is used to designate a trade name. In the United States , the phrase " doing business as " (abbreviated to DBA , dba , d.b.a. , or d/b/a ) is used, among others, such as assumed business name or fictitious business name . In Canada , " operating as " (abbreviated to o/a ) and " trading as " are used, although " doing business as "
5390-398: The use of a symbiotic gel (containing L. acidophilus ) in treating gastrointestinal symptoms in patients who had received a hemodialysis treatment. This gel also reduced the occurrence of vomit, heartburn, and stomachaches. Further study concerning this subject is needed to draw firm conclusions. As stated in a journal from the American Dairy Science Association, " Lactobacillus acidophilus
5467-778: Was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol Myers Squibb, this move was expected to further sharpen the company's focus on biopharmaceuticals. In October 2010, the company acquired ZymoGenetics , securing an existing product, as well as pipeline assets in hepatitis C, cancer, and other therapeutic areas. Bristol Myers Squibb agreed to pay around $ 2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead / Pharmasset to produce hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitex's shareholders acceptance of 126% premium price of its price over
5544-537: Was also effective in reducing Streptococcus mutans levels in saliva, as well as decreasing risk factors associated with the development of nonalcoholic fatty liver disease. The strain of L. acidophilus that has been most widely researched, and is most widely used as a probiotic and is referred to as NCFM. The most common species of Lactobacillus for use in the production of yoghurt is Lactobacillus delbrueckii subsp. bulgaricus . Although probiotics are generally safe, when they are used by oral administration there
5621-596: Was founded in 1858 by Edward Robinson Squibb in Brooklyn , New York. Squibb was known as an advocate of quality control and high purity standards early within the pharmaceutical industry. He went on to self-publish an alternative to the U.S. Pharmacopeia titled Squibb's Ephemeris of Materia Medica, after failing to convince the American Medical Association to incorporate higher purity standards. Materia Medica , Squibb products, and Edward Squibb's opinion on
5698-1005: Was involved in an accounting scandal that resulted in a significant restatement of revenues from 1999 to 2001. The restatement was the result of an improper booking of sales related to " channel stuffing " as the practice of offering excess inventory to customers to create higher sales numbers. The company has since settled with the United States Department of Justice and Securities and Exchange Commission , agreeing to pay $ 150 million, while neither admitting nor denying guilt. On 24 October 2002, Bristol-Myers Squibb Co. restated earnings downward for parts of 2000 and 2001, while revising 2002 earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations. On 15 March 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and full-year 2003 results after reversing an earlier decision about how to deal with accounting errors made in prior years. As part of
5775-545: Was known as Captain Pepple in trade matters, and King Jubo Jubogha of Opobo , who bore the pseudonym Captain Jaja . Both Pepple and Jaja would bequeath their trade names to their royal descendants as official surnames upon their deaths. In Singapore , there is no filing requirement for a "trading as" name, but there are requirements for disclosure of the underlying business or company's registered name and unique entity number. In
5852-476: Was ranked as the best drug company of 2013 by Forbes magazine . In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies. In February 2015, the company initiated a research partnership with Rigel Pharmaceuticals which could generate more than $ 339 million. In March,
5929-453: Was valued at over US$ 81.6 billion in October 2018. In 2018, 85% of the company's revenues came from just five products. In 2018, Bristol-Myers Squibb spent 36% of its total revenue on R&D expenses. Bristol-Myers Squibb ranked 145th on the Fortune 500 list of the largest United States corporations by revenue in 2018. Bristol Myers Squibb reported Total CO2e emissions (Direct + Indirect) for
#336663